<DOC>
	<DOC>NCT00743483</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy in patients with cystic fibrosis and pancreatic insufficiency following treatment with BSSL</brief_summary>
	<brief_title>Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency</brief_title>
	<detailed_description>In this open study, patients will enter a baseline period of 6 days where the pancreatic enzyme therapy will be discontinued and a standard diet given. After the baseline period, patients will enter a treatment period of 6 days where a fixed dose of BSSL will be administered. The primary efficacy measurements will be made by collecting stool during the last three days of each period.</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>Patients with cystic fibrosis and pancreatic insufficiency who are able to refrain from their ongoing pancreatic enzyme treatment for a period of 7 days and are able to produce stools &gt;= 5 times per week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>pancreatic insufficiency</keyword>
	<keyword>bucelipase alfa</keyword>
	<keyword>bile salt stimulating lipase</keyword>
	<keyword>BSSL</keyword>
	<keyword>coefficient of fat absorption</keyword>
</DOC>